Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer
Aligos Therapeutics (NASDAQ:ALGS) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Here's Why Aligos Therapeutics (NASDAQ:ALGS) Must Use Its Cash Wisely [Yahoo! Finance]
Aligos Therapeutics (NASDAQ:ALGS) is now covered by analysts at UBS Group AG. They set a "buy" rating on the stock.
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)